Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The company achieved a revenue of 2.04 billion yuan in H1 2025, representing a year-on-year increase of 2.6%, with a net profit attributable to the parent company of 160 million yuan, up 4.3% [1] - The report highlights the successful expansion of new channels in China and the positive operational dynamics of the BF segment [1][2] - The company is actively seeking opportunities to divest its PC business, which is expected to significantly enhance performance flexibility if successful [11] Summary by Sections Revenue and Profitability - In H1 2025, the company reported revenues of 2.04 billion yuan, with a gross margin of 33.2% and a net margin of 6.7% [1] - The revenue breakdown for H1 2025 shows China, Europe, and the Americas contributing 8.2 billion, 3.6 billion, and 7.6 billion yuan respectively, with year-on-year growth rates of -1.6%, +22.0%, and +4.3% [2] - The gross margin in H1 2025 increased by 1.1 percentage points compared to the previous year, indicating stable profitability [4] Regional Performance - The Chinese market experienced a slight revenue decline in Q2 2025 due to order confirmation timing, but overall orders showed double-digit growth [2] - The Americas region maintained growth despite tariff disruptions, with a revenue increase of 7.4% in H1 2025 [3] - The European market outperformed expectations with a revenue growth of 22% in H1 2025, driven by the introduction of standardized products [3] Future Outlook - The company forecasts revenue growth for 2025-2027 to be 46.4 billion, 52.5 billion, and 59.2 billion yuan, with corresponding net profits of 3.5 billion, 4.7 billion, and 5.4 billion yuan [11] - The report anticipates a recovery trend in the Chinese market, supported by a low base effect [11]
仙乐健康(300791):25年中报点评:中国新渠道拓展卓有成效,关注BF经营动态